CNMV - Other relevant information

Cookies notice

This website uses its own cookies and third-party cookies for technical, customisation, and analysis of behavioural advertising purposes. The latter provides data regarding browsing habits (such as the pages visited) and determine profiles to improve our content.

For further information, please read our Cookies Policy

This website contains links from third-party websites that may contain cookies not belonging to the CNMV. By viewing and accessing them, you accept the cookies installed by third parties and their corresponding privacy and cookies policy.

This website uses cookies and/or similar technologies that store and retrieve information when browsing. For further information, see our Cookies Policy

Technical cookies

Used for the website’s proper functioning.

Customisation cookies

They retrieve information in order for the user to access the service with certain characteristics that may change their experience from that of other users. For example, the language selected or other options that allow for an improved accessibility within the website.

Analytics cookies

Third party (Google). These allow for follow-up and user behaviour analysis for the purpose of incorporating improvements to the website’s content.

Behavioural advertising cookies

Third party (Google). They store information on user behaviour obtained through ongoing observation of their browsing habits, allowing for the development of a specific profile for information content optimisation.

PHARMA MAR, S.A.

from 23/03/2026 to 23/03/2026

- 23/03/2026
- 19:08
- PHARMA MAR, S.A.
- Other relevant information
- The Executive Committee of Pharma Mar, S.A. has decided to implement the Stock Ownership Plan approved by resolution of the General Shareholders’ Meeting of 18 June 2025.
- Register number: 39861
- 23/03/2026
- 08:23
- PHARMA MAR, S.A.
- On business and financial situation
- Taiwanese health authorities approve the combination of PharmaMar's Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) as first-line maintenance therapy for advanced small cell lung cancer.
- Register number: 39834